1.Birmaher, B, Brent, DA, Benson, RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1998;37:1234–1238.
2.Lewinsohn, PM, Rohde, P, Seeley, JR. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev. 1998;18:765–794.
3.Geller, B, Zimerman, B, Williams, M, Bolhofner, K, Craney, JL. Adult psychosocial outcome of prepubertal major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:673–677.
4.Birmaher, B, Ryan, ND, Williamson, DE, et al.Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry. 1996;35:1427–1439.
5.Emslie, GJ, Rush, AJ, Weinberg, WA, et al.A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031–1037.
6.Wagner, KD, Ambrosini, P, Rynn, M, et al.Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. 2003;290:1033–1041.
7.Wagner, KD, Robb, AS, Findling, RL, Jin, J, Gutierrez, MM, Heydorn, WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004;161:1079–1083.
8.Wagner, KD, Jonas, J, Findling, RL, Ventura, D, Saikali, K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280–288.
9.Cheung, AH, Emslie, GJ, Mayes, TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005;46:735–754.
10.Nixon, MK, Milin, R, Simeon, JG, Cloutier, P, Spenst, W. Sertraline effects in adolescent major depression and dysthymia: a six-month open trial. J Child Adolesc Psychopharmacol. 2001;11:131–142.
11.Rynn, M, Wagner, KD, Donnelly, C, et al.Long-term sertraline treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006;16:103–116.
12.Emslie, GJ, Heiligenstein, JH, Hoog, SL, et al.Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43:1397–1405.
14.Hammad, TA, Laughren, T, Racoosin, J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63:332–339.
15.Montgomery, SA, Entsuah, R, Hackett, D, Kunz, NR, Rudolph, RL. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry. 2004;65:328–336.
16.Simon, JS, Aguiar, LM, Kunz, NR, Lei, D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res. 2004;38:249–257.
17.Thase, ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry. 1997;58:393–398.
18.Emslie, GJ, Findling, RL, Yeung, PP, Kunz, NR, Li, Y. Venlafaxine ER for the treatment of pediatric patients with depression: results of 2 placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. In press.
19.Hughes, CW, Emslie, GJ, Crismon, ML, et al.The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:1442–1454.
20.Kaufman, J, Birmaher, B, Brent, D, et al.Schedule for affective disorders and schizophrenia for school-age children–present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–988.
21.Poznanski, EO, Freeman, LN, Mokros, HB. Children's depression rating scale-revised. Psychopharmacol Bull. 1985;21:979–989.
22.Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Department of Health, Education, and Welfare; 1976:217–222. Publication ADM 76-338.
23.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
24.Kennard, BD, Silva, S, Vitiello, B, et al.Remission and residual symptoms after acute treatment of adolescents with major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:1404–1411.
25.Kusiak, V. Dear Healthcare Professional (venlafaxine). August 22, 2003. Collegeville, Penn: Wyeth Pharmaceuticals.
27.Findling, RL, McNamara, NK, Stansbrey, RJ, et al.The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol. 2006;16:131–145.
28.Greenhill, L, Vitiello, B, Riddle, M, et al.Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2003;42:627–633.